Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection
Joo‐Yun Byun, Yi Ting Koh, Sun Young Jang, Jennifer Witcher, Jason R. Chan, Anna Pustilnik, Mark Daniels, Young‐Hoon Kim, Kwee Hyun Suh, Matthew D. Linnik, Young-Mi LeeScientific2021 · DOI
The selective Bruton tyrosine kinase (BTK) inhibitor poseltinib has demonstrated significant potential in modulating B-cell signaling pathways. This study details the translation of preclinical research into a Phase I clinical trial, utilizing high-dimensional phosphorylation analysis and Quantitative Systems Pharmacology (QSP) modeling to establish a robust link between target occupancy and clinical efficacy. These findings informed the selection of a 5 mg minimally effective dose for Phase II trials in rheumatoid arthritis.
Introduction
Selecting optimal dosages for Phase II clinical trials is a critical challenge in drug development, particularly for autoimmune diseases like rheumatoid arthritis (RA). While Phase I trials provide safety and pharmacokinetic (PK) data, they lack efficacy endpoints. To bridge this gap, researchers must translate animal disease models to human biology. This study focuses on poseltinib, a selective and covalent BTK inhibitor designed to disrupt the B-cell signaling driving autoimmune responses.
Chemical structure of poseltinib, a selective and covalent BTK inhibitor.
A multi-tiered approach was employed to map poseltinib's behavior across biological scales:
High-Dimensional Phosphoflow Cytometry: "Pathway Phenotyping" measured 94 intracellular signaling nodes across various immune cells to identify the drug's specific signaling "fingerprint."
Preclinical Disease Modeling: A rat model of collagen-induced arthritis (CIA) was used to correlate drug concentration and BTK occupancy with physical improvements in joint health.
Phase I Clinical Trial: A randomized, double-blind study (NCT01765478) in 90 healthy volunteers evaluated human PK and target engagement using an ELISA-based occupancy assay.
Quantitative Systems Pharmacology (QSP) Modeling: PK/PD data were integrated into a computational model to simulate virtual patient populations and predict clinical outcomes, such as ACR20 response scores.
Key Insights and Results
Selectivity and Target Engagement
Phosphoflow analysis revealed that poseltinib is highly specific, strongly inhibiting signaling in B cells (via BTK/PLCγ2/AKT) while having minimal impact on T and NK cells. This suggests a lower risk of broad immunosuppression.
High-dimensional phosphorylation analysis comparing signaling nodes, illustrating the selective impact of poseltinib on specific immune pathways.
Due to its covalent binding, poseltinib maintains high target occupancy even after plasma clearance. In the Phase I trial, doses of 40 mg maintained >80% occupancy for up to 48 hours.
Preclinical and Clinical Efficacy
In the rat CIA model, 3 mg/kg of poseltinib significantly reduced arthritis scores and inhibited bone erosion and cartilage degradation by approximately 38% and 37%, respectively. The QSP model successfully mapped this relationship onto human data, predicting that a 5 mg dose would be the minimally effective dose for RA treatment.
Discussion and Conclusion
The study confirms poseltinib as a potent and selective BTK inhibitor with desirable PK/PD properties. The use of BTK occupancy as a translatable biomarker, combined with QSP modeling, allowed for a rational, model-informed approach to dose selection. While the current data are derived from healthy volunteers, the selective nature of poseltinib makes it a strong candidate for further investigation in RA and other B-cell-mediated diseases, including multiple sclerosis.
Summary updated
Abstract
The selective Bruton tyrosine kinase (BTK) inhibitor poseltinib has been shown to inhibit the BCR signal transduction pathway and cytokine production in B cells (Park et al. Arthritis Res. Ther. 18, 91, https://doi.org/10.1186/s13075-016-0988-z , 2016). This study describes the translation of nonclinical research studies to a phase I clinical trial in healthy volunteers in which pharmacokinetics (PKs) and pharmacodynamics (PDs) were evaluated for dose determination. The BTK protein kinase inhibitory effects of poseltinib in human peripheral blood mononuclear cells (PBMCs) and in rats with collagen-induced arthritis (CIA) were evaluated. High-dimensional phosphorylation analysis was conducted on human immune cells such as B cells, CD8 + memory cells, CD4 + memory cells, NK cells, neutrophils, and monocytes, to map the impact of poseltinib on BTK/PLC and AKT signaling pathways. PK and PD profiles were evaluated in a first-in-human study in healthy donors, and a PK/PD model was established based on BTK occupancy. Poseltinib bound to the BTK protein and modulated BTK phosphorylation in human PBMCs. High-dimensional phosphorylation analysis of 94 nodes showed that poseltinib had the highest impact on anti-IgM + CD40L stimulated B cells, however, lower impacts on anti-CD3/CD-28 stimulated T cells, IL-2 stimulated CD4 + T cells and NK cells, M-CSF stimulated monocytes, or LPS-induced granulocytes. In anti-IgM + CD40L stimulated B cells, poseltinib inhibited the phosphorylation of BTK, AKT, and PLCγ2. Moreover, poseltinib dose dependently improved arthritis disease severity in CIA rat model. In a clinical phase I trial for healthy volunteers, poseltinib exhibited dose-dependent and persistent BTK occupancy in PBMCs of all poseltinib-administrated patients in the study. More than 80% of BTK occupancy at 40 mg dosing was maintained for up to 48 h after the first dose. A first-in-human healthy volunteer study of poseltinib established target engagement with circulating BTK protein. Desirable PK and PD properties were observed, and a modeling approach was used for rational dose selection for subsequent trials. Poseltinib was confirmed as a potential BTK inhibitor for the treatment of autoimmune diseases.Trial registration: This article includes the results of a clinical intervention on human participants [NCT01765478].
BibTeX
@inproceedings{byun2021target,
author = {Joo‐Yun Byun and Yi Ting Koh and Sun Young Jang and Jennifer Witcher and Jason R. Chan and Anna Pustilnik and Mark Daniels and Young‐Hoon Kim and Kwee Hyun Suh and Matthew D. Linnik and Young-Mi Lee},
title = {{Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection}},
booktitle = {Scientific},
year = {2021},
doi = {10.1038/s41598-021-98255-7},
}